The Manufacturers Life Insurance Company Purchases 227,589 Shares of Merck & Co., Inc. $MRK

The Manufacturers Life Insurance Company grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 12.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,073,176 shares of the company’s stock after acquiring an additional 227,589 shares during the period. The Manufacturers Life Insurance Company’s holdings in Merck & Co., Inc. were worth $266,403,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in MRK. California State Teachers Retirement System grew its stake in Merck & Co., Inc. by 12,537.4% during the second quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company’s stock worth $62,286,552,000 after purchasing an additional 480,884,635 shares during the period. Norges Bank bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $3,997,933,000. Wellington Management Group LLP increased its stake in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after acquiring an additional 11,156,354 shares in the last quarter. Cardano Risk Management B.V. acquired a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $1,012,530,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Merck & Co., Inc. by 37.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after acquiring an additional 5,152,069 shares during the period. 76.07% of the stock is owned by institutional investors.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the sale, the executive vice president owned 36,613 shares in the company, valued at approximately $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David Williams sold 52,847 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 over the last three months. Corporate insiders own 0.17% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on MRK. Guggenheim lifted their price target on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday. Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price for the company in a research note on Wednesday, August 12th. Weiss Ratings raised Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Finally, Jefferies Financial Group downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Seventeen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $151.32.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts raised price targets: HSBC lifted its target from $150 to $172 and maintained a “buy” rating, while Guggenheim raised its target to $170. Leerink Partners also increased its target from $127 to $161 and assigned an “outperform” rating. These revisions indicate continued confidence in Merck’s earnings potential and pipeline. Guggenheim Increases Merck Price Target
• Positive Sentiment: Pipeline strategy may help address Keytruda risks: Merck is pairing antibody-drug conjugates with Keytruda in women’s cancer treatments, an effort to expand its oncology franchise and offset the eventual impact of Keytruda’s patent cliff. Merck Pairs ADCs With Keytruda
• Neutral Sentiment: Investors are reassessing Merck’s valuation: A comparison with Eli Lilly highlights that Merck is trading at a higher valuation despite its slower expected growth, prompting questions about whether its pipeline, cash generation and defensive characteristics justify the premium. Merck Stock Versus Eli Lilly
• Neutral Sentiment: Market attention remains elevated: Merck was among the stocks most watched by Zacks users, suggesting strong investor interest but not necessarily a change in fundamentals. Merck Investor Attention
• Negative Sentiment: Shares declined with the broader market and underperformed during the session: The trading update provided no new company-specific catalyst, leaving valuation concerns and the Keytruda patent-cliff debate as the primary pressures on the stock.

Merck & Co., Inc. Stock Down 1.9%

MRK opened at $144.68 on Friday. The company has a market cap of $356.96 billion, a PE ratio of 115.75, a price-to-earnings-growth ratio of 6.42 and a beta of 0.21. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a 50 day moving average of $136.22 and a 200 day moving average of $124.26.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter last year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.